Invicta Diagnostic Limited
About Invicta Diagnostic Limited
Data last updated:
Invicta Diagnostic Limited is a public limited company based in Mumbai, Maharashtra, India. It was incorporated on 01 December 2023.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L86100MH2023PLC414723. Its shares are listed on NSE: INVICTA.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.57 Cr. It is led by directors including Sanket Vinod Jain (Managing Director) and Aayush Kamleshbhai Shah.
Its last annual general meeting (AGM) was held on 29 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹32.35 Cr, a growth of 7.5% compared to the previous year. For the same year it recorded a net profit of ₹4.44 Cr (net margin 13.7%) and EBITDA of ₹9.75 Cr (EBITDA margin 30.1%). The net worth stands at ₹49.92 Cr (up 267.1% YoY). Total assets are valued at ₹53.7 Cr (up 211.7% YoY).
The company has about 1 employee on its provident fund (EPFO) records.
The company is associated with 1 brand: PC Diagnostics. The company has 1 deal on record (1 ipo); the latest was in December 2025. Its 10 peer companies in the Healthcare industry (Diagnostics and Pathology Labs) are compared by revenue, 5 larger and 5 smaller; the largest is Auro Mri Centre Private Limited with revenue of ₹31.64 Cr.
CIN History of Invicta Diagnostic Limited
Invicta Diagnostic has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L86100MH2023PLC414723, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L86100MH2023PLC414723 | Current |
| U86100MH2023PTC414723 | Previous |
| U86100MH2023PLC414723 | Previous |
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address1 GF Plot 217 Ambavat, Bhavan N.M Joshi Marg, Mumbai, Maharashtra, India – 400013
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands with Invicta Diagnostic Limited
Invicta Diagnostic operates one associated brand: PC Diagnostics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers pathology, imaging, and cardiology services through diagnostic centers in India. | pcdiagnostics.in |
Business Activity of Invicta Diagnostic Limited
The main business activity of Invicta Diagnostic is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q2 | Medical and dental practice, Nursing, pathology, blood bank services, etc. | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Invicta Diagnostic Limited FY 2025-26 filings available
Invicta Diagnostic Limited reported revenue of ₹32.35 Cr (up 7.5% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 32.35 | 30.10 | 7.99 |
| Revenue growth | +7.5% | +276.7% | - |
| EBITDA | 9.75 | 9.21 | 3.39 |
| EBITDA margin | +30.1% | +30.6% | +42.4% |
| Profit before tax | 6.99 | 6.58 | 2.68 |
| Net profit | 4.44 | 4.90 | 2.68 |
| Net profit margin | +13.7% | +16.3% | +33.5% |
| EPS (₹) | 3.90 | 5.81 | 204.49 |
| Balance sheet | |||
| Total assets | 53.70 | 17.23 | 13.01 |
| Net worth | 49.92 | 13.60 | 12.18 |
| Total debt | 3.67 | 3.53 | 1.87 |
| Cash & bank | 22.21 | 2.16 | 1.34 |
| Net working capital | 29.57 | 3.69 | 1.47 |
| Cash flow | |||
| Cash from operations | 2.93 | 6.56 | 4.21 |
| Cash from investing | (13.67) | (5.23) | (10.01) |
| Cash from financing | 30.79 | (0.50) | 7.14 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 20.28 | 16.27 | 3.50 |
| Revenue growth | +24.7% | +364.9% | - |
| EBITDA | 7.66 | 6.20 | 1.47 |
| EBITDA margin | +37.8% | +38.1% | +42.0% |
| Profit before tax | 7.26 | 6.68 | 2.42 |
| Net profit | 5.10 | 5.22 | 2.40 |
| Net profit margin | +25.2% | +32.1% | +68.6% |
| EPS (₹) | 4.40 | 6.21 | 182.53 |
| Balance sheet | |||
| Total assets | 49.20 | 14.73 | 9.43 |
| Net worth | 49.09 | 12.78 | 9.43 |
| Total debt | 0.00 | 1.86 | 0.00 |
| Cash & bank | 21.21 | 0.80 | 0.89 |
| Net working capital | 25.42 | 2.91 | 0.89 |
| Cash flow | |||
| Cash from operations | 3.20 | 2.79 | 5.05 |
| Cash from investing | (12.60) | (2.75) | (9.51) |
| Cash from financing | 29.80 | (0.12) | 5.35 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 32.35 | 30.10 | 7.99 |
| Revenue growth | +7.5% | +276.7% | - |
| Other income | 0.69 | 0.09 | 0.35 |
| Total expenses | 22.60 | 20.89 | 4.60 |
| Employee cost | 4.77 | 4.69 | 1.09 |
| EBITDA | 9.75 | 9.21 | 3.39 |
| EBITDA margin | +30.1% | +30.6% | +42.4% |
| Depreciation | 3.25 | 2.49 | 0.98 |
| Interest | 0.20 | 0.23 | 0.08 |
| Profit before tax | 6.99 | 6.58 | 2.68 |
| Tax | 2.13 | 1.64 | 0.00 |
| Net profit | 4.44 | 4.90 | 2.68 |
| Net profit margin | +13.7% | +16.3% | +33.5% |
| EPS (₹) | 3.90 | 5.81 | 204.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 12.57 | 8.42 | 0.13 |
| Reserves & surplus | 37.35 | 5.18 | 12.05 |
| Shareholders' funds (net worth) | 49.92 | 13.60 | 12.18 |
| Minority interest | 0.00 | 0.00 | (1.03) |
| Secured loans | 3.67 | 1.57 | 1.87 |
| Unsecured loans | 0.00 | 1.96 | 0.00 |
| Total debt | 3.67 | 3.53 | 1.87 |
| Total liabilities | 53.70 | 17.23 | 13.01 |
| Assets | |||
| Gross block | 33.95 | 21.09 | 17.22 |
| Net block | 19.20 | 9.58 | 11.79 |
| Capital work in progress | 0.00 | 0.00 | 0.00 |
| Investments | 6.20 | 4.33 | 0.00 |
| Inventories | 0.59 | 0.50 | 0.39 |
| Sundry debtors | 0.57 | 1.46 | 0.82 |
| Cash & bank balances | 22.21 | 2.16 | 1.34 |
| Loans & advances | 10.93 | 2.27 | 1.16 |
| Total current assets | 34.30 | 6.39 | 3.71 |
| Total current liabilities | 4.73 | 2.70 | 2.24 |
| Net working capital | 29.57 | 3.69 | 1.47 |
| Total assets | 53.70 | 17.23 | 13.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 2.16 | 1.34 | 0.00 |
| Net cash from operating activities | 2.93 | 6.56 | 4.21 |
| Net cash from investing activities | (13.67) | (5.23) | (10.01) |
| Net cash from financing activities | 30.79 | (0.50) | 7.14 |
| Net change in cash | 20.05 | 0.83 | 1.34 |
| Closing cash | 22.21 | 2.16 | 1.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +7.5% | +276.7% | - |
| EBITDA growth | +5.9% | +171.7% | - |
| PBT growth | +6.2% | +145.5% | +9997.0% |
| Net income growth | -9.4% | +82.8% | - |
| Profitability & leverage | |||
| Net income margin | +15.0% | +16.4% | +33.5% |
| Return on capital employed | +20.3% | +43.4% | +19.7% |
| Return on net worth | +15.3% | +38.3% | +22.1% |
| Debt / equity | 0.11 | 0.21 | 0.15 |
| Long-term debt / equity | 0.03 | 0.08 | 0.00 |
| Interest cover | 3.08 | 3.42 | 3.32 |
| Efficiency & per share | |||
| Fixed asset turnover | 1.18 | 1.57 | 0.46 |
| Inventory turnover | 59.36 | 67.64 | 20.49 |
| Debtors turnover | 31.87 | 26.40 | 9.74 |
| EPS (₹) | 3.90 | 5.81 | 204.49 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 39.71 | 16.15 | 925.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 20.28 | 16.27 | 3.50 |
| Revenue growth | +24.7% | +364.9% | - |
| Other income | 1.13 | 1.46 | 1.34 |
| Total expenses | 12.62 | 10.07 | 2.03 |
| Employee cost | 2.81 | 2.36 | 0.61 |
| EBITDA | 7.66 | 6.20 | 1.47 |
| EBITDA margin | +37.8% | +38.1% | +42.0% |
| Depreciation | 1.49 | 0.95 | 0.38 |
| Interest | 0.04 | 0.03 | 0.01 |
| Profit before tax | 7.26 | 6.68 | 2.42 |
| Tax | 1.73 | 1.46 | 0.02 |
| Net profit | 5.10 | 5.22 | 2.40 |
| Net profit margin | +25.2% | +32.1% | +68.6% |
| EPS (₹) | 4.40 | 6.21 | 182.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 12.57 | 8.42 | 0.13 |
| Reserves & surplus | 36.52 | 4.36 | 9.30 |
| Shareholders' funds (net worth) | 49.09 | 12.78 | 9.43 |
| Secured loans | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 1.86 | 0.00 |
| Total debt | 0.00 | 1.86 | 0.00 |
| Total liabilities | 49.20 | 14.73 | 9.43 |
| Assets | |||
| Gross block | 13.82 | 8.72 | 4.97 |
| Net block | 7.42 | 3.81 | 4.59 |
| Capital work in progress | 0.00 | 0.00 | 0.00 |
| Investments | 16.64 | 8.00 | 4.20 |
| Inventories | 0.39 | 0.36 | 0.29 |
| Sundry debtors | 0.50 | 2.39 | 0.71 |
| Cash & bank balances | 21.21 | 0.80 | 0.89 |
| Loans & advances | 6.27 | 1.55 | 0.04 |
| Total current assets | 28.37 | 5.10 | 1.93 |
| Total current liabilities | 2.95 | 2.19 | 1.04 |
| Net working capital | 25.42 | 2.91 | 0.89 |
| Total assets | 49.20 | 14.73 | 9.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 0.80 | 0.89 | 0.00 |
| Net cash from operating activities | 3.20 | 2.79 | 5.05 |
| Net cash from investing activities | (12.60) | (2.75) | (9.51) |
| Net cash from financing activities | 29.80 | (0.12) | 5.35 |
| Net change in cash | 20.40 | (0.08) | 0.89 |
| Closing cash | 21.21 | 0.80 | 0.89 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +24.7% | +364.9% | - |
| EBITDA growth | +23.6% | +321.8% | - |
| PBT growth | +8.7% | +176.0% | +9997.0% |
| Net income growth | -2.3% | +117.5% | - |
| Profitability & leverage | |||
| Net income margin | +27.3% | +32.1% | +68.6% |
| Return on capital employed | +22.8% | +55.6% | +25.8% |
| Return on net worth | +17.9% | +47.1% | +25.5% |
| Debt / equity | 0.03 | 0.08 | 0.00 |
| Long-term debt / equity | 0.03 | 0.08 | 0.00 |
| Interest cover | 0.65 | 0.57 | 0.92 |
| Efficiency & per share | |||
| Fixed asset turnover | 1.80 | 2.38 | 0.70 |
| Inventory turnover | 54.08 | 50.06 | 12.07 |
| Debtors turnover | 14.03 | 10.50 | 4.93 |
| EPS (₹) | 4.40 | 6.21 | 182.53 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 39.05 | 15.18 | 717.10 |
Board of Directors of Invicta Diagnostic Limited
Invicta Diagnostic has 4 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Aayush Kamleshbhai Shah Also directs: Raghuvir Synthetics Limited, Siddhi Cotspin Limited, H.M. Electro Mech Limited and 2 more | Director | 12 Jul 2024 | 2 Years 3 Months | Current |
| Shilpa Ajay Bhatia | Director | 12 Jul 2024 | 2 Years 3 Months | Current |
| Ketan Jayantilal Jain Also directs: Primacare Diagnostic LLP, Porteus Medical LLP, Invicta Diagnostic Healthplus LLP and 1 more | Director | 15 Jan 2024 | 2 Years 9 Months | Current |
| Sanket Vinod Jain Also directs: Primacare Diagnostic LLP, Porteus Medical LLP, Invicta Diagnostic Healthplus LLP and 5 more | Managing Director | 15 Jan 2024 | 2 Years 9 Months | Current |
Peer Comparison of Invicta Diagnostic Limited
Invicta Diagnostic Limited is compared with the companies closest to it by revenue in the Healthcare industry (Diagnostics and Pathology Labs). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Invicta Diagnostic Limited this company | ₹32.35 Cr (FY 2026) | •••• | •••• | 7.5% | •••• | Mumbai, Maharashtra, India |
| Auro Mri Centre Private Limited | ₹31.64 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Tamluk, West Bengal, India |
| Pankaj Scanning and Pathology Research Centre Pvt.Ltd. | ₹31.51 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Uttar Pradesh, India |
| Mapmygenome India Limited | ₹31.2 Cr (FY 2025) | •••• | •••• | 2.0% | •••• | Hyderabad, Telangana, India |
| K S K Diagnostics Private Limited | ₹31.07 Cr (FY 2025) | •••• | •••• | 39.0% | •••• | Coimbatore, Tamil Nadu, India |
| Medicare Health Services Private Limited | ₹31.06 Cr (FY 2025) | •••• | •••• | 0.0% | •••• | Srinagar, Jammu and Kashmir, India |
| Nirman Hitech Diagnostic Centre Private Limited | ₹30.43 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Mumbai, Maharashtra, India |
| Eko-Diagnostic Pvt Ltd | ₹30.21 Cr (FY 2025) | •••• | •••• | -23.0% | •••• | Cal, West Bengal, India |
| Meerut Medicare Centre Private Limited | ₹30.12 Cr (FY 2025) | •••• | •••• | 12.0% | •••• | Uttar Pradesh, India |
| Micro Health Laboratories Private Limited | ₹29.96 Cr (FY 2024) | •••• | •••• | 1397.0% | •••• | Kozhikode, Kerala, India |
| Igenomix India Private Limited | ₹29.93 Cr (FY 2024) | •••• | •••• | 19.0% | •••• | New Delhi, Delhi, India |
Peers are the five companies nearest above and the five nearest below Invicta Diagnostic by revenue in the Healthcare industry (Diagnostics and Pathology Labs), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Charges & Borrowings of Invicta Diagnostic Limited
Invicta Diagnostic Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Invicta Diagnostic Limited
Invicta Diagnostic Limited has 1 deal on record (1 ipo); the latest was in December 2025.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2025 | IPO | ₹28.13 Cr | Investors: Shine Star Build-Cap Private Limited , Rajasthan Global Securities Private Limited , Holani Venture Capital Fund |
Full deal history
All 1 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Employees and EPFO Compliance at Invicta Diagnostic Limited
Employment history and EPFO contributions of people linked to Invicta Diagnostic.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Invicta Diagnostic Limited
Invicta Diagnostic Limited has 12 board changes on record since 2024: 4 appointments and 8 cessations. The latest: Aayush Kamleshbhai Shah was appointed as Director on 12 Jul 2024.
3 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Invicta Diagnostic Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Invicta Diagnostic Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Invicta Diagnostic Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Invicta Diagnostic Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Invicta Diagnostic Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Invicta Diagnostic Limited
Invicta Diagnostic is an active public limited company based in Mumbai, Maharashtra, India. It was incorporated on 01 December 2023 (3+ years old) and is registered under CIN L86100MH2023PLC414723. Listed on NSE: INVICTA.
Invicta Diagnostic reported revenue of ₹32.35 Cr for FY 2025-26 (up 7.5% YoY) based on consolidated financials.
Invicta Diagnostic has 4 current directors:
- Sanket Vinod Jain - Managing Director
- Aayush Kamleshbhai Shah - Director
- Shilpa Ajay Bhatia - Director
- Ketan Jayantilal Jain - Director
The CIN (Corporate Identification Number) of Invicta Diagnostic is L86100MH2023PLC414723. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Invicta Diagnostic is listed on NSE with symbol INVICTA.
Invicta Diagnostic was incorporated on 01 December 2023, making it 3+ years old. It is registered with the Registrar of Companies, Mumbai.
Invicta Diagnostic has 1 deal on record (1 ipo); the latest was in December 2025.
The peers of Invicta Diagnostic by revenue are Auro Mri Centre Private Limited, Pankaj Scanning and Pathology Research Centre Pvt.Ltd, Mapmygenome India Limited, K S K Diagnostics Private Limited, Medicare Health Services Private Limited and 5 more, all in the Healthcare industry (Diagnostics and Pathology Labs).
Aayush Kamleshbhai Shah was appointed as Director on 12 Jul 2024. Shilpa Ajay Bhatia was appointed as Director on 12 Jul 2024. Rohit Prakash Srivastava ceased to be Additional Director on 25 Mar 2024. Invicta Diagnostic has 12 board changes on record in total.
The registered office of Invicta Diagnostic is at 1 GF Plot 217 Ambavat, Bhavan N.M Joshi Marg, Mumbai, Maharashtra, India – 400013.
Invicta Diagnostic has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.57 Cr.